8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

February 27, 2019

Date of Report (Date of earliest event reported)

PARATEK PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware	001-36066	33-0960223
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
75 Park Plaza Boston, MA		02116
(Address of principal executive offices)		(Zip Code)

(617) 807-6600

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§ 240 12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On February 27, 2019, Paratek Pharmaceuticals, Inc., (the “Company”) issued a press release containing an update on its recent business activities as well as those for the quarter and full year ended December 31, 2018. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The Company will host a conference call and live audio webcast on Wednesday, February 27, 2019 at 4:30 p.m. EST to report fourth quarter and year end 2018 financial results and provide a corporate update. As part of this call, the Company will deliver the slide presentation attached to this report as Exhibit 99.2, which is incorporated herein by reference.

The information in this report, including Exhibits 99.1 and 99.2, is being furnished pursuant to Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Exhibits.

(d) Exhibits.

Number	Description
99.1	Paratek Pharmaceuticals, Inc. Press Release dated February 27, 2019.
99.2	Paratek Pharmaceuticals, Inc. presentation for earnings call for the quarter and year ended December 31, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PARATEK PHARMACEUTICALS, INC.
Date: February 27, 2019	By:	/s/ Douglas W. Pagán
		Douglas W. Pagán
		Chief Financial Officer

EX-99.1

Exhibit 99.1

Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

-- NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI --

-- New England Journal of Medicine Publishes Results from Two Pivotal Phase 3 Studies of NUZYRA --

-- Company Executes SEYSARA™ Royalty-Backed Loan to Receive $32.5 Million --

BOSTON, February 27, 2019 -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today reported financial results and provided an update on corporate activities for the quarter and full year ended December 31, 2018.

“2018 was a transformative year for Paratek. The FDA approved NUZYRA, the first once-daily oral and IV antibiotic to treat both CABP and ABSSSI in nearly 20 years, as well as SEYSARA for the treatment of moderate to severe acne.  Both products launched commercially in the U.S. earlier this year” said Michael Bigham, Chairman and Chief Executive Officer, Paratek.  “We believe that NUZYRA has the potential to shape the future treatment paradigm for serious community-acquired pneumonia and skin infections.”

“2019 will be an important year for Paratek,” said Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer.  “In addition to the U.S. launch of NUZYRA, we continue to pursue several compelling life-cycle opportunities including two phase 2 studies in UTI, collaborating with the Department of Defense for plague and anthrax and exploring the potential of an oral-only indication in CABP.  We believe these initiatives have the potential to treat patients in need and drive additional long-term value for all shareholders.  We look forward to keeping you apprised of our progress on these promising opportunities.”

Recent Highlights

• Executed a royalty-backed loan agreement with Healthcare Royalty Partners III, L.P. (HCRP) to borrow $32.5 million to be funded May 1, 2019, which will be secured by and repaid from royalties received by Paratek from the net sales of SEYSARA in the United States by Almirall, LLC.

• New England Journal of Medicine (NEJM) published 2 manuscripts with detailed results from the Company’s Phase 3 clinical trials (OPTIC and OASIS-1) of NUZYRA™ (omadacycline) highlighting the potential clinical impact that NUZYRA can have on the practice of medicine in an era of growing resistance to older antibiotic agents.

• NUZYRA launched in the United States in February 2019 as a once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).

o In concert with the U.S. launch, three antimicrobial susceptibility tests are now available for use with NUZYRA.  Paratek has also launched the KEYSTONE^TM surveillance program to monitor omadacycline susceptibility.  

• The Company’s partner, Almirall, launchedSEYSARA^TM in the U.S., in January 2019.  SEYSARA is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of moderate to severe acne in the community setting.  Paratek is entitled to receive tiered royalties at rates ranging from high single to low double digits of net U.S. sales of SEYSARA and retains all ex-U.S. rights.

• Filed two patent term extensions for NUZYRA in the United States; the Company now expects patent protection until at least October 2030, two years beyond the ten years of exclusivity provided by the Hatch-Waxman and GAIN Acts.

• Dosed the first patient in a Phase 2 study evaluating the potential efficacy and safety of oral and intravenous (IV) omadacycline for the treatment of acute pyelonephritis, a common subset of complicated urinary tract infections (cUTI).

• The European Marketing Authorization Application for oral and IV omadacycline was submitted in October 2018 and the review has been initiated.   

o The Company is seeking approval for the treatment of CABP and ABSSSI. 

Fourth Quarter and Full Year 2018 Financial Results

For the fourth quarter of 2018, Paratek reported a net loss of $22.8 million, or ($0.71) per share, compared to a net loss of $21.9 million, or ($0.78) per share, for the same period in 2017.  For the year ended December 31, 2018, Paratek reported a net loss of $112.4 million, or ($3.57) per share, compared to a net loss of $89.1 million, or ($3.32) per share, for the same period in 2017.  

Revenue earned during the year ended December 31, 2018 of $17.1 million was $4.5 million higher than revenue earned during the same period in prior year.   Revenue earned during the year ended December 31, 2018 was primarily attributable to a $12.0 million milestone earned from Almirall, LLC upon FDA approval of SEYSARA and a $5.0 million milestone earned from Zai Lab upon FDA approval of NUZYRA.  Revenue earned during the year ended December 31, 2017 of $12.6 million was primarily attributable to a $7.5 million upfront payment received as part of an omadacycline collaboration agreement with Zai Lab and a $5.0 million milestone payment earned from Allergan plc on FDA acceptance of the SEYSARA NDA.

Research and development expenses were $11.8 million and $57.5 million for the quarter and year ended December 31, 2018, respectively, compared to $14.2 million and $60.1 million for the same periods in 2017.  The slight decrease for both periods was driven primarily by lower clinical study costs, offset by higher compensation-related costs, including stock-based compensation expense, manufacturing production costs for omadacycline and costs associated with additional regulatory activities.

General and administrative expenses were $25.3 million and $63.7 million for the quarter and year ended December 31, 2018, respectively, compared to $11.7 million and $37.0 million for the same periods in 2017.  The increase in general and administrative expenses for both periods was due to higher compensation-related costs associated with increased headcount and stock-based compensation expense as well as increased spend related to the U.S. launch of NUZYRA.

Based upon Paratek’s current operating plan, the Company anticipates that its existing cash, cash equivalents and marketable securities of $292.8 million as of December 31, 2018, estimated NUZYRA product sales, and SEYSARA royalty-backed loan with HCRP will fund company operating expenses, capital expenditures, and debt service beyond the first quarter of 2021.

Financial Guidance

Paratek also reiterated its 2019 NUZYRA U.S. net product revenue guidance, expected to be between $10.0 and $13.0 million.  Paratek may experience events that could cause actual results to vary from this guidance.  Paratek plans to provide one update to its annual financial guidance, which is expected to be provided in connection with its second quarter earnings release.

Conference Call and Webcast

Paratek’s earnings conference call for the quarter and year ended December 31, 2018 will be broadcast today at 4:30 p.m. EDT onFebruary 27, 2019. The live webcast can be accessed under "Events and Presentations" in the Investor Relations section of Paratek’s website at www.ParatekPharma.com.

Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. The conference ID is 13687655. Investors can also access the call at http://public.viavid.com/index.php?id=133293.

Website Information

Paratek routinely posts important information for investors on the Investor Relations section of its website at www.ParatekPharma.com. Paratek intends to use this website as a means of disclosing material, non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Paratek’s website, in addition to following its press releases, U.S. Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Paratek’s website is not incorporated by reference into, and is not a part of, this document.

About Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company’s lead commercial product, NUZYRA (omadacycline), which has launched and is available in the U.S., is a once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek is also studying NUZYRA for the treatment of urinary tract infections (UTI).  

Paratek has submitted a marketing authorization application of omadacycline in the European Union. Paratek has entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.  

Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax. 

Paratek’s second FDA-approved product, SEYSARA™ (sarecycline), is marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. Paratek retains development and commercialization rights in the rest of the world. 

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.  

For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter. 

Forward Looking Statements 

This press release contains forward-looking statements including statements related to our overall strategy, products, prospects, potential and expected results, including statements about the projected net product revenues of NUZYRA™, our anticipated cash runway, our expected borrowings under our royalty-backed loan agreement with Healthcare Royalty Partners III, L.P., the progression of our commercial roll out for NUZYRA™, the prospects of our U.S. launch of NUZYRA™, our ability to shape the future treatment paradigm for serious community-acquired pneumonia and skin infections, our plans to evaluate additional indications for NUZYRA™, including UTI, and to work toward an oral-only indication in CABP, our potential to further drive long-term[, transformative] value for all of our shareholders, our expectations regarding the duration of our patent protection exclusivity for NUZYRA™ and our plans to obtain regulatory approval of omadacycline in the European Union .  All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2017, our Form 10-Q filed for the quarter ended September 30, 2018 and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

PARATEK PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)

	December 31, 2018			December31, 2017
	(unaudited)
Cash, cash equivalents and marketable securities		$   292,838	$   151,723
Total assets		300,192	163,698
Working capital		237,534	143,697
Total current liabilities		17,709	16,789
Long-term debt, less current portion		228,959	59,186
Common stock and additional paid-in-capital		630,174	552,748
Accumulated deficit		(582,468)	(470,112		)
Total stockholders' equity		47,578	82,478

Condensed Consolidated Statements of Operations(unaudited)(in thousands, except loss per share data)

	Three Months Ended December 31,		Year Ended December 31,
	2018	2017	2018	2017
Revenue
Collaboration and royalty revenue	$      17,017	$        5,072	$      17,117	$   12,616
Total revenue	17,017	5,072	17,117	12,616
Operating expenses:
Research and development	11,802	14,225	57,508	60,072
General and administrative	25,263	11,665	63,658	36,965
Impairment of intangible assets	—	62	107	743
Changes in fair value of contingent consideration	(14)	(13)	(71)	(584)
Total operating expenses	37,051	25,939	121,202	97,196
Loss from operations			(104,085)	(84,580)
Other income and expenses:
Interest income	968	398	3,260	1,377
Interest expense	(3,191)	(1,413)	(10,985)	(5,079)
Other gains (and losses), net	(30)	(10)	(44)	(34)
Net loss	(22,290)	(21,892)	(111,854)	(88,316)
Provision for income taxes	502	—	502	753
Net loss attributable to common stockholders	$    (22,791)	$   (21,892)	$  (112,356)	$ (89,069)
Net loss per share attributable to common stockholders:
Basic and diluted net loss per common share	$       (0.71)	$       (0.78)	$        (3.57)	$     (3.32)
Weighted average common shares outstanding
Basic and diluted	32,143,147	27,937,157	31,513,454	26,827,253

CONTACT:

Investor and Media Relations:

Ben Strain

617-807-6688

ir@ParatekPharma.com

EX-99.2

Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update February 27, 2019 Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. Exhibit 99.2

Q4 & FY 2018 Earnings Call Agenda Introduction Ben Strain, Executive Director, Investor Relations & Corporate Communications Fourth Quarter Overview and Business Update Michael F. Bigham, Chief Executive Officer and Chairman of the Board Commercial Update Adam Woodrow, Chief Commercial Officer Financial Update Douglas W. Pagán, Chief Financial Officer Closing Remarks Michael F. Bigham, Chief Executive Officer and Chairman of the Board Also Available for Q&A: Evan Loh, M.D., President, COO & CMO

Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The information contained in this presentation is accurate only as of the date hereof. “Paratek” and the Paratek logo are trademarks and service marks of Paratek. All other trademarks, service marks, trade names, logos and brand names identified in this presentation are the property of their respective owners. This presentation contains forward-looking statements including statements related to our overall strategy, products, prospects, potential and expected results, including statements about the projected net product revenues of NUZYRA™, our anticipated cash runway, our expected borrowings under our royalty-backed loan agreement with Healthcare Royalty Partners III, L.P., the progression of our commercial roll out for NUZYRA™, the prospects of our U.S. launch of NUZYRA™, our ability to shape the future treatment paradigm for serious community-acquired pneumonia and skin infections, our plans to evaluate additional indications for NUZYRA™, including UTI, and to work toward an oral-only indication in CABP, our potential to further drive long-term[, transformative] value for all of our shareholders, our expectations regarding the duration of our patent protection exclusivity for NUZYRA™ and our plans to obtain regulatory approval of omadacycline in the European Union .  All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2017, our Form 10-Q filed for the quarter ended September 30, 2018 and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein. PARATEK® and the Hexagon Logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA and its design logo are trademarks of Paratek Pharmaceuticals, Inc. Safe Harbor Statement

Fourth Quarter & FY 2018 Overview & Business Update Michael F. Bigham, Chief Executive Officer & Chairman of the Board Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

NUZYRATM Approved, Launched & Available in the U.S. First FDA approved, once-daily oral and IV antibiotic to treat both CABP and ABSSSI in nearly 20 years Launched in U.S. February 2019

The New England Journal of Medicine  Published results from the OPTIC and OASIS-1 Phase 3 clinical trials of NUZYRA Publication affirmation of the potential positive clinical impact NUZYRA can play in supporting the battle against the growing health challenge of antibiotic resistance Once-daily oral and IV NUZYRA safe and effective in adults with pneumonia and skin infections, demonstrating clinical activity against relevant pneumonia- and skin-associated drug resistant bacteria Highlights The New England Journal of Medicine Published February 7, 2019 N Engl J Med 2019; 380:517-527; DOI: 10.1056/NEJMoa1800201 (Link to Article) N Engl J Med 2019; 380:528-538; DOI: 10.1056/NEJMoa1800170 (Link to Article)

NUZYRA IP Protection and Market Exclusivity GAIN Act Ensures 10 Yrs.’ Market Exclusivity and Patent Term Extension protection to at least 2030 Patent Term Extension (PTE) Key Composition of Matter Patent (U.S. 7,553,828) Expires June 2023 2000 2005 2010 2015 2020 2025 2030 ‘828 Patent Issued Approval GAIN Act Extension - In Parallel - U.S. Data Exclusivity: Hatch Waxman 5-years 5-years IP Protection: Regulatory Protection: Issued Patents and Pending Applications Covering Salts, Polymorphs, Formulations, Methods of Use, Methods of Manufacture, Modes of Administration, and Dosage Regimens Follow-On IP Protection: 2035 PTE Key Method of Use Patent (U.S. 9,265,740) Expires March 2029 ‘740 Patent Issued

Paratek Pipeline Compelling Life-cycle Opportunities Research Preclinical Phase 1 Phase 2 Phase 3 Registration Marketed+ Commercial Rights SEYSARATM (sarecycline) (U.S.) (ex-U.S.) (Global*) uUTI (Oral only) – QIDP ABSSSI (IV & Oral) – QIDP + SPA CABP (IV & Oral) – QIDP + SPA Inflammatory Acne (Acne Vulgaris) +Marketed in the US only *We have entered into a collaboration agreement with Zai Lab (Shanghai) Co., Ld., for the greater China region # Acute pyelonephritis is a subset of cUTI; Acute pyelonephritis is a common subset of complicated UTI’s where the kidneys become infected ABSSSI (Oral only ) – QIDP Biodefense Pathogens NUZYRA 100mg for injection & 150mg tablets FDA Animal Rule Applies Acute Pyelonephritis# (IV & Oral) – QIDP

Strengthening the Balance Sheet Summary of Deal terms: Non-recourse, SEYSARA royalty-backed loan with HealthCare Royalty Partners Principal amount of $32.5 million, to be funded May 1, 2019 Interest rate 12% per annum paid quarterly Royalty payments in excess of accrued interest on the loan will be used to repay principal until the balance is fully repaid Once the loan has been paid back in full, the value will revert back to the benefit of Paratek 

Strong Track Record Delivering on Milestones Omadacycline Events Timing Results ABSSSI Phase 3 data: IV & oral Q2 2016 Positive Phase 3 data UTI Phase 1b data: PK/PD Q4 2016 Proof-of-principle CABP Phase 3 data: IV & oral Q2 2017 Positive Phase 3 data ABSSSI Phase 3 data: Oral-only Q3 2017 Positive Phase 3 data NDA approval Oct 2018 Approved U.S. Launch Feb 2019 Launched Projected EMA Approval H2 2019 UTI Phase 2 data: uUTI & Acute Pyelonephritis H2 2019 Sarecycline Events1 Timing Results Phase 3 efficacy studies Q1 2017 Positive Phase 3 data NDA Approval Oct 2018 Approved U.S. Launch Jan 2019 Launched Almirall, LLC licensed U.S. development & commercial rights

Commercial Update Adam Woodrow, Chief Commercial Officer  Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

More Oral Options New Therapies to Overcome Drug Resistance Greater Safety Alternative to Quinolones There are Unmet Needs that NUZYRA Will Address Reduce Hospital Length of Stay Reduce Nursing Time Lack of Different Class Options Reduce Usage of Multi-Drug Combinations NUZYRA Attributes Provide A Modern-Day Solution Unmet Need Confirmed Through Physician Research Known Safety Profile Established Efficacy in a Monotherapy Equivalent IV & Oral Physicians Recognize the Positive Attributes of NUZYRA Modernized Tetracycline Confidence to Discharge Patient Once Daily Dosing Reduce Nursing Time Lower C.diff Potential Source: Paratek Sponsored Market Research Reduce Usage of Multi-Drug Combinations

Ensure Seamless Transition from Hospital to Home Continuity of Care Providing Access to Oral NUZYRA Continuity of Care Prevent gap in care Sample / Bridge Program (as needed) Reimbursement Support Services Affordability Program 3 Distribution Network IV Formulation National & Regional Distributors Oral Formulation National & Regional Pharmacies Program allows for oral formulation pick-up at retail locations or home delivery HUB Services Enables effective discharge process

Success Begins in the Hospital with Specialists “Go-Home” Strategy to Minimize Hospital Stay IDs ER HCPs Hospitalists Pulmonologists PharmD IDs Allied HCPs Launch and Beyond HOSPITAL Internal Medicine Primary Care Provider NPs, PAs Urgent Care Year 2 and Beyond COMMUNITY

Focused Launch Targeting Early Adopters Expansion to ~80 Representatives by Year End 2019 Physician Segments Guideline and protocol driven Wait for Early Adopters to trial and use Convenient features with IV to oral transition Focused on broad spectrum and efficacy Launch in February 2019 with 40 Sales Specialists Focusing on ‘Early Adopting’ HCPs in ‘high value’ institutions (~400), will drive institutional access By end of 2019, plan to have a total of ~80 Sales Specialists targeting 800 institutions Inside Sales Team will supplement efforts of Sales Specialists and broaden outreach Early Adopter Late Adopter

Additional Tools to Support NUZYRA Adoption

Influencers: IDs PharmD IDs Pharmacy Directors Microbiologists = Field Force Has Two Simultaneous Objectives Institutional Access + Demand Generation Adoption Formulary/Protocols Specialty Access & Buying + Institutional Access Prescribers: IDs ER Hospitalists Pulmonologists Trial & Usage Demand Generation

Early Indicators to Track Performance 1 Covered Lives Institutional Access 3 months Post-Launch 33% of covered lives under contract 12 months Post-Launch 66% of covered lives under contract 12 months Post-Launch 70% of 800 targeted institutions

Financial Update Douglas W. Pagán, Chief Financial Officer Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Condensed Consolidated Statements of Operations (unaudited)  (in thousands, except loss per share data)  Three Months Ended December 31, Year Ended December 31, 2018 2017   2018 2017 Revenue Collaboration and royalty revenue $ 17,017 $ 5,072 $ 17,117 $ 12,616 Total revenue 17,017 5,072 17,117 12,616 Operating expenses: Research and development 11,802 14,225 57,508 60,072 General and administrative 25,263 11,665 63,658 36,965 Impairment of intangible assets — 62 107 743 Changes in fair value of contingent consideration (14) (13) (71) (584) Total operating expenses 37,051 25,939 121,202 97,196 Loss from operations (104,085) (84,580) Other income and expenses: Interest income 968 398 3,260 1,377 Interest expense (3,191) (1,413) (10,985) (5,079) Other gains (and losses), net (30) (10) (44) (34) Net loss (22,290) (21,892) (111,854) (88,316) Provision for income taxes 502 — 502 753 Net loss attributable to common stockholders $ (22,791) $ (21,892) $ (112,356) $ (89,069) Net loss per share attributable to common stockholders: Basic and diluted net loss per common share $ (0.71) $ (0.78) $ (3.57) $ (3.32) Weighted average common shares outstanding Basic and diluted 32,143,147 27,937,157 31,513,454 26,827,253

Strong Balance Sheet Key Metrics (unaudited) 12/31/18 balance Total Cash, Cash Equivalents, and Marketable Securities $292.8 million Long-term Debt Obligation $229.0 million Basic Shares Outstanding 32,284,602 Total Potentially Dilutive Securities*  16,709,048 * Includes common stock issuable under the April 2018 convertible debt offering, options, restricted share units, warrants, and for our ESPP ** Includes proceeds from $32.5 million SEYSARA royalty-backed loan closed in February 2019 Cash runway now projected beyond Q1 2021**

2019 U.S. NUZYRA Net Product Revenue Guidance Today: Slower starts…But with the Right Attributes, a Strong Finish Recent AB Launches: antibiotics launched since 2010 that have at least 36 months of data - Avycaz, Dalvance, Orbactiv, Sivextro, Teflaro, & Zerbaxa (does not include Dificid or new formulations/line extensions) *MAT = 12-month rolling total 2019 NUZYRA Net Product Revenue Guidance (U.S.) $10 mill. - $13 mill. Assumes a U.S. NUZYRA WAC price of $345 per vial for IV use, WAC price of $197.50 per tablet for oral use, and launch in February 2019 U.S. launch (11 months) * *

Closing Remarks Michael F. Bigham, Chief Executive Officer & Chairman of the Board Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Well-Positioned for Future Growth Focused on Execution + New Value Creation Near-term Focus New Value Creation Launch of NUZYRA  Prudent Operating Expense Management Non-Dilutive Sources of Capital Life-cycle Opportunities for NUZYRA Bio-Defense Product / Pipeline Expansion